Sänkta läkemedelspriser med referensprissystemet

Lakartidningen

Volumn , Issue 23, 1998, Pages 2715-2717

  Bergman, Mats A ^a   Aronsson, Thomas ^b   Rudholm, Niklas ^b,c  

^a Handelshogskolan Och K ^*

^b HANKEN SCHOOL OF ECONOMICS   (Finland)

^c UMEÅ UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG;

ARTICLE; DRUG COST; SWEDEN;

DRUG COSTS; DRUGS, GENERIC; SWEDEN;

EID: 0032478899     PISSN: 00237205     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Läkemedelsmarknaden. Stockholm: Statens pris-och konkurrensverk, 1990.
2. Socialdepartementet. Reform på recept [delbetänkande av HSU 2000]. SOU 1995: 12.
3. Aronsson T, Bergman M, Rudholm N. The impact of generic competition on brand name market shares - Evidence from micro data. Umeå: institutionen for nationalekonomi, Umeå universitet, 1997.
4. Schwartzman D. Innovations in the pharmaceutical industry. Baltimore: Johns Hopkins University Press, 1976.
5. Statman M. The effect of patent expiration on the market positions of drugs. Management and Decisions Economics 1981; 2: 61-6.
6. McRay JJ, Tapon F. Some empirical evidence on post-patient barriers to entry in the Canadian pharmaceutical industry. Journal of Health Economics 1985; 4: 43-61.
7. Huruwitz MA, Caves RE. Persuation or information? Promotion and the market shares of brand name and generic pharmaceuticals. Journal of Law and Economics 1988; 31: 299-320.
8. Grabowski HG, Vernon JM. Brand loyalty, entry and price competition in pharmaceuticals after the 1984 Drug Act. Journal of Law and Economics 1992; 35: 331-50.
9. Redwood H. The pharmaceutical industry: trends, problems, achievements. Suffolk: Oldwicks Press Ltd, 1988.
10. US Congressional Budget Office. How health care reform affects pharmaceutical research and development. Washington: US Government Printing Office, 1994.
11. Hartley K, Lavers RJ, Maynard AK. Regulation and development times in the UK pharmaceutical industry. Scottish Journal of Political Economy 1986; 33: 355-69.
12. Craig AM, Malek M. Market structure and conduct in the pharmaceutical industry. Pharmacol Ther 1995; 66: 301-37.
13. Nilsson JLG, Nilsson A, Lundh K. Användningen av generiska läkemedel i Sverige. Stockholm: Apotekarsocieteten/NEPI, 1998.
14. Behandling av mild till måttlig hypertoni. SBU vill strama upp diagnostik och terapi. Läkartidningen 1994; 91: 1536-40.
15. Werkö L. Kalciumkanalhämmare riskabel medicin? Dålig uppföljning trots tidig varning. Läkartidningen 1996; 93: 1440-4.